CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2017--
Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome
therapeutics platform company, today announced that management will
participate in two upcoming investor conferences:
-
Canaccord Genuity Rare Disease and BioPharma 1x1 Day on Tuesday,
February 7, 2017 in New York, NY
-
6th Annual Leerink Partners Global Healthcare Conference onWednesday, February 15, 2017 in New York, NY; presentation at 11:00
a.m. ET
Live audio webcast of the Leerink presentation be available under the
“Investors and Media” section of Seres’ website. A replay of the
presentation will become available approximately one hour after the
event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a
leading microbiome therapeutics platform company developing a novel
class of biological drugs that are designed to treat disease by
restoring the function of a dysbiotic microbiome, where the natural
state of bacterial diversity and function is imbalanced. The Phase 2
study of Seres' program SER-109 has been completed in multiply recurrent C.
difficile infection. Seres' second clinical candidate, SER-287,
is being evaluated in a Phase 1b study in patients with mild-to-moderate
ulcerative colitis (UC). Seres is also developing SER-262, the first
ever synthetic microbiome therapeutic candidate, in a Phase 1b study in
patients with primary C. difficile infection. For more
information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170203005081/en/
Source: Seres Therapeutics Inc.
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of
Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com
